Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

Updates arrive automatically.

  • GATX Corporation Reports 2026 Third-Quarter Results
    PR·

    GATX Corporation Reports 2026 Third-Quarter Results

    Third-quarter diluted earnings per share increased to $2.92 from $2.25 in the prior-year period Company expects 2026 full-year earnings to modestly exceed the high end of its previously announced guidance range Rail North America fleet utilization increased to 98.4% at quarter end Demand for aircraft spare engines remains strong Investment volume was $171.7 million in the third quarter and totaled over $4.8 billion year to date GATX Corporation (NYSE:GATX) today reported 2026 third-quarter net income attributable to GATX of $105.2 million, or $2.92 per diluted share, compared to net income attributable to GATX of $82.2 million, or $2.25 per diluted share, in the third quarte

    $GATX
  • More Than 100 HCA Healthcare Hospitals Recognized by Healthgrades for Excellence in Specialty Care
    PR·

    More Than 100 HCA Healthcare Hospitals Recognized by Healthgrades for Excellence in Specialty Care

    HCA Healthcare hospitals earned more 2027 specialty care recognitions than any other health system, including national distinctions for surgical care, emergency medicine and orthopedic surgery HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that 102 of its hospitals have been recognized by Healthgrades for excellence in specialty care, more than any other health system in the country. The 2027 recognitions reflect clinical outcomes in important areas of patient care, including surgical care, emergency medicine and orthopedic surgery. For patients and families making healthcare decisions, these recognitions provide information about hosp

    $HCA
  • Graham Holdings Company Reports Third Quarter Earnings
    PR·

    Graham Holdings Company Reports Third Quarter Earnings

    Graham Holdings Company (NYSE:GHC) today reported its financial results for the third quarter of 2026. The Company also filed its Form 10-Q today for the quarter ended September 30, 2026 with the Securities and Exchange Commission. Division Operating Results Revenue for the third quarter of 2026 was $1,326.0 million, up 4% from $1,278.9 million in the third quarter of 2025. The Company reported operating income of $85.5 million for the third quarter of 2026, compared to $67.1 million for the third quarter of 2025. The Company reported adjusted operating cash flow (non-GAAP) of $121.8 million for the third quarter of 2026, compared to $110.1 million for the third quarter of 2025. Revenue

    $GHC
  • Lumen is Redefining Networking for the AI and Quantum Eras
    PR·

    Lumen is Redefining Networking for the AI and Quantum Eras

    Lumen advances intelligent networking with Emerald AI, The Ohio State University, and Fortinet to address AI energy demands and prepare for the quantum future Lumen Technologies (NASDAQ:LUMN) today announced three new initiatives using intelligent networking to address AI energy challenges, future quantum connectivity, and emerging security threats. As enterprises’ AI and quantum ambition begin to outgrow traditional networks, Lumen is turning its network into an active platform for innovation—combining fiber connectivity scale, programmable control, software intelligence, and a connected ecosystem of partners to help enable the next generation of computing. This press release features m

    $LUMN
  • SentinelOne to Add Anthropic’s Claude Mythos 5.1 to Wayfinder Frontier AI Services
    PR·

    SentinelOne to Add Anthropic’s Claude Mythos 5.1 to Wayfinder Frontier AI Services

    SentinelOne offering pairs security experts with Anthropic’s most capable model class for cybersecurity as AI-fueled attacks and exploits become the new normal SentinelOne® (NYSE:S), the AI Security leader, today announced the upcoming addition of Anthropic Claude Mythos 5.1 to its Wayfinder Frontier AI Services offering. Designed to help customers proactively secure their code and digital operations from AI-scaled threats, Wayfinder Frontier AI Services find which vulnerabilities exist, hone in on which are truly exploitable today, and then offer remediation guidance and support to quickly address risks. Finding the Signal in the Wave In the last few weeks, the cybersecurity landscap

    $S
  • Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures
    PR·

    Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures

    Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide Just 2% Penetration of Estimated U.S. Epidural Procedure Market Represents $33 Million in Potential Annual Disposable Revenue Medical Segment Revenue Increased 200%+ in Q2 2026 as Company Advances Commercial

    $MLSS
  • Veritone to Hold Third Quarter 2026 Results Conference Call on November 12th
    PR·

    Veritone to Hold Third Quarter 2026 Results Conference Call on November 12th

    Veritone, Inc. (NASDAQ:VERI), a leader in enterprise AI and data solutions, today announced the details of its third quarter 2026 financial results conference call. Veritone will hold a conference call on Thursday, November 12, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time), to discuss its results for the third quarter 2026, provide an update on the business and conduct a question-and-answer session. To participate, please join the conference call or live audio webcast links or use the following dial-in numbers and ask to be connected to the Veritone earnings conference call. To avoid any delays, please join at least fifteen minutes prior to the start of the call. Conferenc

    $VERI
  • Alliance Entertainment to Host First Quarter Fiscal Year 2027 Results Conference Call on November 12 at 4:30 p.m. Eastern Time
    PR·

    Alliance Entertainment to Host First Quarter Fiscal Year 2027 Results Conference Call on November 12 at 4:30 p.m. Eastern Time

    Alliance Entertainment Holding Corporation (NASDAQ:AENT), a scaled entertainment commerce and collectibles platform serving content owners, brands, retailers and fans across music, movies, gaming, licensed merchandise and collectibles, with proprietary brands, authentication technology and reach across more than 35,000 retail and e-commerce storefronts, will hold a conference call on Thursday, November 12, at 4:30 p.m. Eastern Time to discuss its results for the first quarter of fiscal year 2027 ended September 30, 2026. A press release detailing these results will be issued prior to the call. Alliance Entertainment Chief Executive Offic

    $AENT
  • TOMI Environmental Solutions Secures Three-Phase SteraMist iHP Order from Mexican Pharmaceutical Manufacturer Zeyco
    PR·

    TOMI Environmental Solutions Secures Three-Phase SteraMist iHP Order from Mexican Pharmaceutical Manufacturer Zeyco

    TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ:TOMZ), a global leader in disinfection and decontamination solutions, today announced it has received a three-phase order valued at approximately $402,000 from Zeyco, a Mexican company dedicated to developing and manufacturing medicines and medical devices, as a global player in the market of dental anesthetics injectable cartridges. The order covers the phased deployment of SteraMist ionized Hydrogen Peroxide (iHP) decontamination across three aseptic manufacturing lines at Zeyco's facility in Guadalajara, Jalisco, including the rooms supporting the filling of injectable solutions. It a

    $TOMZ
  • Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
    PR·

    Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026

    Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 5, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the third quarter of 2026. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutica

    $QNRX
  • Marchex to Report Third Quarter 2026 Financial Results on Tuesday, November 10, 2026
    PR·

    Marchex to Report Third Quarter 2026 Financial Results on Tuesday, November 10, 2026

    Marchex, Inc. (NASDAQ:MCHX) ("Marchex" or the "Company"), a vertically focused, AI-driven conversation analytics, customer acquisition and optimization company, today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, November 10, 2026, after the close of the market. At that time, Marchex will post the press release in the Press Center section of its corporate website (https://www.marchex.com/about-us/press/). Following the release, management will hold a conference call at 5:00 p.m. ET on Tuesday, November 10, 2026, to discuss the results and outlook for the company. A live webcast will

    $MCHX
  • Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
    PR·

    Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

    Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique p

    $LXRX
  • IperionX – September 2026 Quarterly Report
    PR·

    IperionX – September 2026 Quarterly Report

    IperionX Limited (Nasdaq | ASX: IPX) is pleased to present its quarterly report for the period ended September 30, 2026. Highlights during and subsequent to the end of the quarter include: Operations – Titanium powder and product manufacturing HAMR™ Furnace Capacity Validated Above 200 tpa: HAMR™ titanium powder production continued to ramp on a 24/7 schedule, completing 1.6 tons of back-to-back deoxygenation runs in 63 hours and validated furnace capacity above the 200 tpa target annualized run-rate. Aerospace-Grade Quality: HAMR™ powder consistently met or exceeded Grade 5 titanium quality specifications, confirming HAMR™ as a commerc

    $IPX
  • InterDigital Announces Financial Results for Third Quarter 2026
    PR·

    InterDigital Announces Financial Results for Third Quarter 2026

    New license agreements drive Q3 results above guidance and increased FY26 outlookAnnualized recurring revenue1 at all-time high of $629 millionRevenue up 17% YoY; Net income up 19% YoY; Adjusted EBITDA2 up 25%

    $IDCC
  • Axe Compute Chooses Miami as Global Headquarters for its Neocloud AI Infrastructure Business
    PR·

    Axe Compute Chooses Miami as Global Headquarters for its Neocloud AI Infrastructure Business

    Axe Compute Inc. (NASDAQ:AGPU), a neocloud AI infrastructure platform delivering dedicated enterprise GPU compute capacity at global scale, today announced the relocation of its corporate headquarters from Pittsburgh, Pennsylvania, to Miami, Florida. The Company's new headquarters will be located at 801 Brickell Avenue, Suite 510, Miami, FL 33131. The relocation establishes Axe Compute's corporate headquarters in one of the United States' leading international business and financial centers, providing greater proximity to strategic partners, investors and a growing network of global business relationships. With its international connectivity, acces

    $AGPU
  • Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
    PR·

    Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

    Celcuity Inc. (NASDAQ:CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-186

    $CELC
  • West Bancorporation, Inc. Announces Third Quarter 2026 Financial Results and Declares Quarterly Dividend
    PR·

    West Bancorporation, Inc. Announces Third Quarter 2026 Financial Results and Declares Quarterly Dividend

    West Bancorporation, Inc. (NASDAQ:WTBA, the "Company")), parent company of West Bank, today reported third quarter 2026 net income of $11.6 million, or $0.67 per diluted common share, compared to second quarter 2026 net income of $11.1 million, or $0.64 per diluted common share, and third quarter 2025 net income of $9.3 million, or $0.55 per diluted common share. On October 28, 2026, the Company’s Board of Directors declared a regular quarterly dividend of $0.26 per common share. The dividend is payable on November 25, 2026, to stockholders of record on November 11, 2026. David Nelson, President and Chief Executive Officer of the Co

    $WTBA
  • Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
    PR·

    Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

    Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ETALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy Data from the Phase 1 RESOLUTION Study Scheduled for November 9, 2026 at 6:00 a.m. PT/9:00 a.m. ETPreliminary Data from the Phase 1 RESOLUTION Trial will also be Presented at American College of Rheumatology (ACR) Convergence 2026

    $ALLO